US biotech major Biogen (Nasdaq: BIIB) announced on Friday that head of R&D Douglas Williams will leave the company at the end of July to become chief executive of an as-yet unnamed start-up biotechnology company. Dr Williams will be the first member of a new organization with potential in cancer diagnostics and therapy.
Responsibility for Biogen research and development will be assumed by Alfred Sandrock, senior vice president and chief medical officer, and Spyros Artavanis-Tsakonas, senior vice president and chief scientific officer. Both Dr Sandrock and Dr Artavanis-Tsakonas currently serve on the executive management team.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze